ID   LNCaP-abl
AC   CVCL_4793
SY   LNCaP-ABL; LNCaP-androgen ablation
DR   BTO; BTO_0006467
DR   cancercelllines; CVCL_4793
DR   GEO; GSM3145719
DR   GEO; GSM5402195
DR   Wikidata; Q54902830
RX   PubMed=10496349;
RX   PubMed=34402095;
RX   PubMed=38892296;
CC   Population: Caucasian.
CC   Characteristics: Established after 10 months of propagation of LNCaP in steroid-depleted medium.
CC   Karyotypic information: Has lost chromosome Y.
CC   Sequence variation: Mutation; HGNC; HGNC:644; AR; Simple; p.Thr878Ala (c.2632A>G); ClinVar=VCV000009831; Zygosity=Hemizygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:7010; MEN1; Simple; p.Tyr318Ter (c.954T>G) (p.Tyr313Ter, c.939T>A); ClinVar=VCV000439894; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:8979; PIK3R1; Simple; p.Arg639Ter (c.1915C>T); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:9588; PTEN; Simple; p.Lys6Argfs*4 (c.17_18delAA); ClinVar=VCV000231649; Zygosity=Unspecified (from parent cell line).
CC   Omics: Transcriptomics; RNAseq.
CC   Misspelling: LNCaP-abI; BTO=BTO_0006467.
CC   Derived from site: Metastatic; Left supraclavicular lymph node; UBERON=UBERON_8480056.
DI   NCIt; C4863; Prostate carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0395 ! LNCaP
SX   Male
AG   50Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 10-04-25; Version: 25
//
RX   PubMed=10496349; DOI=10.1038/sj.bjc.6690684; PMCID=PMC2362859;
RA   Culig Z., Hoffmann J., Erdel M., Eder I.E., Hobisch A., Hittmair A.,
RA   Bartsch G., Utermann G.W., Schneider M.R., Parczyk K., Klocker H.;
RT   "Switch from antagonist to agonist of the androgen receptor
RT   bicalutamide is associated with prostate tumour progression in a new
RT   model system.";
RL   Br. J. Cancer 81:242-251(1999).
//
RX   PubMed=34402095; DOI=10.1002/pros.24210; PMCID=PMC8460612;
RA   Haffner M.C., Bhamidipati A., Tsai H.K., Esopi D.M., Vaghasia A.M.,
RA   Low J.-Y., Patel R.A., Guner G., Pham M.-T., Castagna N., Hicks J.L.,
RA   Wyhs N., Aebersold R., De Marzo A.M., Nelson W.G., Guo T.-N.,
RA   Yegnasubramanian S.;
RT   "Phenotypic characterization of two novel cell line models of
RT   castration-resistant prostate cancer.";
RL   Prostate 81:1159-1171(2021).
//
RX   PubMed=38892296; DOI=10.3390/ijms25116111; PMCID=PMC11172770;
RA   Beatson E.L., Risdon E.N., Napoli G.C., Price D.K., Chau C.H.,
RA   Figg W.D. Sr.;
RT   "Genomic characterization of preclinical prostate cancer cell line
RT   models.";
RL   Int. J. Mol. Sci. 25:6111.1-6111.19(2024).
//